Analysts have significantly lowered their price target for Lifeward from $8.00 to approximately $5.17. They cite more conservative revenue growth projections and a notable reduction in expected profit margins.
What's in the News
- Lifeward Ltd. reaffirmed its earnings guidance for the full year 2025, projecting revenue between $24 and $26 million. (Key Developments)
- The company announced completion of a $3 million private placement through the issuance of secured convertible promissory notes. These notes are convertible into ordinary shares at $0.45 per share, carry a 15% annual interest rate, and mature in May 2026, with participation from Oramed Ltd. (Key Developments)
- Lifeward received its first payment from a commercial Medicare Advantage Plan for a ReWalk 7 Personal Exoskeleton. With the establishment of a Medicare reimbursement pathway, the claims process has accelerated and most Medicare approvals now occur at initial submission, reducing processing times to 30-60 days. (Key Developments)
Valuation Changes
- The consensus analyst price target has decreased significantly from $8.00 to approximately $5.17.
- The discount rate has risen slightly from 9.43% to 9.65%.
- The revenue growth forecast has fallen from 58.8% to 49.6%.
- The net profit margin estimate has dropped sharply from 14.8% to 1.4%.
- The projection for the future P/E ratio has increased substantially from 13.7x to 114.1x.
Have other thoughts on Lifeward?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.